Skip to content


Press Releases
Press Releases
Werewolf Therapeutics Appoints Tim Trost as Chief Financial Officer
Veteran life sciences financial executive brings over 25 years finance and capital markets expertise Cambridge, Mass., February 8, 2021 – Read More
Werewolf Therapeutics Completes $72 Million Series B Financing to Advance a Novel Class of Cancer Biotherapeutics to the Clinic
Financing accelerates Werewolf’s pipeline of systemically delivered, conditionally activated INDUKINE™ molecules into clinical stage development and supports efforts to build Read More
Werewolf Therapeutics Appoints Dr. Randi Isaacs as Chief Medical Officer
Expansion of leadership team with deep translational oncology drug development expertise as Company prepares for clinical development of lead programs Read More
Werewolf Therapeutics Appoints Business Leader, Ellen Lubman, as Chief Business Officer
Cambridge, Mass., August 10, 2020 – Werewolf Therapeutics, Inc., an oncology biotherapeutics company developing next-generation, transformative cancer therapeutics, today announced Read More
PRESS RELEASE: Werewolf Therapeutics Launches with $56M Series A Financing to Develop Transformative Immuno-Stimulatory Cancer Medicines
Designing conditionally activated therapeutics that unleash a powerful attack on cancer cells Company led by experienced team with proven track Read More
Designing conditionally activated immune stimulators that attack cancer cells
As seen in Nature Biopharma Dealmakers Using its proprietary PREDATOR protein engineering platform, Werewolf designs biotherapeutics that are systemically delivered Read More
Pittsburgh Business Times: UPMC Enterprises invests in immunotherapy startup
UPMC Enterprises is part of the investor group for a Massachusetts startup that focuses on immunotherapies, the types of treatments that Read More
Smart Business Dealmakers Pittsburgh: UPMC Enterprises Invests In Werewolf Therapeutics
UPMC Enterprises joined a Series A funding round of $56 million for Werewolf Therapeutics. The Cambridge, Massachusetts-based oncology biotherapeutics company is developing Read More
FierceBiotech: Werewolf Therapeutics uncloaks with $56M and shape-shifting cancer meds
It’s a full moon for Werewolf Therapeutics as the company comes out of stealth with $56 million and an approach it believes Read More
EndPoints News: MPM and Longwood-backed Werewolf Therapeutics grabs $56 million to take tumors by night
Backed with the team from his last company, one of the key developers behind Keytruda has a new warchest in Read More
Boston Business Journal: Keytruda researcher launches cancer-focused Werewolf Therapeutics with $56M
One of the researchers behind Merck’s blockbuster cancer drug Keytruda has launched a new startup with the aim of expanding Read More
BioWorld: With a howl and a series A, Werewolf Therapeutics is born
Even though November’s full moon had come and gone more than a week previous, Werewolf Therapeutics Inc. came out of Read More
BioCentury: Werewolf debuts with $56M to develop tumor-activated biologics
Emerging from stealth with a $56 million series A round, Werewolf Therapeutics is aiming to increase the therapeutic window of Read More
Wall Street Journal: Biotech Startup Werewolf Therapeutics Hunts Down $56 Million
Biotechnology startup Werewolf Therapeutics Inc. gathered $56 million in venture financing to seek solutions to problems that have hindered a Read More